We are live on ! Find out more
BCYC

Bicycle Therapeutics

87 hedge funds and large institutions have $696M invested in Bicycle Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 34 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

21% more capital invested

Capital invested by funds: $577M → $696M (+$119M)

10% more funds holding

Funds holding: 7987 (+8)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

4.4% less ownership

Funds ownership: 83.59%79.19% (-4.4%)

50% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 34

84% less call options, than puts

Call options by funds: $538K | Put options by funds: $3.29M

Holders
87
Holders Change
+8
Holders Change %
+10.13%
% of All Funds
1.4%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
17
Increased
17
Reduced
34
Closed
8
Calls
$538K
Puts
$3.29M
Net Calls
-$2.76M
Net Calls Change
-$2.76M
Name Holding Trade Value Shares
Change
Change in
Stake
DTC
1
Deep Track Capital
Connecticut
$83.4M -$2.17M -80,955 -3%
RCI
2
Ridgeback Capital Investments
Florida
$67M +$60.8M +2,264,801 New
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$44.5M -$49.9M -1,858,251 -55%
LGM
4
Logos Global Management
California
$42.5M -$15.2M -565,000 -28%
RI
5
RTW Investments
New York
$37.3M -$475K -17,689 -1%
PBA
6
Paradigm Biocapital Advisors
New York
$36.5M +$2M +74,594 +6%
CS
7
Candriam SCA
Luxembourg
$34.8M -$1.53M -57,043 -5%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$29.8M -$6.64M -247,440 -20%
SC
9
Samlyn Capital
New York
$29.2M -$8.21M -306,197 -24%
TCM
10
Tybourne Capital Management
Hong Kong
$26.8M -$3.64M -135,609 -13%
EAM
11
Eventide Asset Management
Massachusetts
$25.3M
BBA
12
Baker Bros. Advisors
New York
$25M
PCH
13
Polar Capital Holdings
United Kingdom
$22.2M +$20.1M +750,000 New
Morgan Stanley
14
Morgan Stanley
New York
$21.4M -$3.71M -138,292 -16%
FLAM
15
First Light Asset Management
Minnesota
$20.6M -$222K -8,289 -1%
SCM
16
Sio Capital Management
New York
$20.2M
Verition Fund Management
17
Verition Fund Management
Connecticut
$11.3M +$867K +32,336 +9%
Axa
18
Axa
France
$11.3M -$807K -30,085 -7%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$11.2M -$7.7M -287,159 -43%
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$10M -$2.11M -78,607 -19%
BNP Paribas Asset Management
21
BNP Paribas Asset Management
France
$8.91M +$8.07M +300,968 New
SCM
22
Soleus Capital Management
Connecticut
$7.65M +$6.93M +258,400 New
PVI
23
Pura Vida Investments
New York
$7.07M +$695K +25,894 +12%
BlackRock
24
BlackRock
New York
$5.62M +$235K +8,771 +5%
Millennium Management
25
Millennium Management
New York
$4.99M +$689K +25,677 +18%

BCYC Hedge Fund Activity: Q4 2022 in Review

87 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q4 2022, worth a combined $696M — up 21% from $577M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BCYC positions and 8 closed out — a net gain of 9 holders — while 17 added to existing stakes and 34 trimmed.

The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $20.1M. The largest seller was Janus Henderson Group, cutting an estimated $49.9M.

  • 87 institutional investors held Bicycle Therapeutics (BCYC) as of Q4 2022, up from 79 in Q3 2022.
  • Funds reported $696M of Bicycle Therapeutics stock for Q4 2022, up 21% quarter-over-quarter.
  • 17 funds opened new Bicycle Therapeutics positions in Q4 2022 and 8 closed out, a net change of +9 holders.
  • The largest Bicycle Therapeutics buyer in Q4 2022 was Polar Capital Holdings, an estimated $20.1M added.
  • The largest Bicycle Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $49.9M sold.

Based on aggregated 13F filings for Q4 2022.